What Is Aprea Therapeutics, Inc. (APRE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aprea Therapeutics, Inc. is potentially undervalued at its current price of $0.70. Based on our 13-model framework, Aprea Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $2.34 — representing +235.7% implied upside — with 6 out of 7 active models confirming this thesis. Model dispersion is worth noting: Sentiment SOTP targets $3.96 (+467.9%), versus PWERM at $0.69 (-1.4%). This +469.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About APRE?
7 of 13 models are currently active for APRE. Of these, 6 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates APRE's intrinsic value at $2.20, implying +214.6% upside from the current price. See which stocks rank higher →
How Does APRE Rank in Biotechnology?
Among 76 Biotechnology stocks, APRE ranks #51 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Aprea Therapeutics, Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.
Is APRE a Value Trap?
CirclFi's Value Trap algorithm assigns APRE a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Aprea Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Aprea Therapeutics, Inc. scores 4.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +469.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every APRE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across APRE's 7 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad